Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Current Liabilities (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 4 years of Total Current Liabilities data on record, last reported at $965.0 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities changed N/A year-over-year to $965.0 million; the TTM value through Sep 2025 reached $965.0 million, changed N/A, while the annual FY2024 figure was $924.0 million, 27.87% down from the prior year.
  • Total Current Liabilities reached $965.0 million in Q3 2025 per INDV's latest filing, down from $1.1 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $1.3 billion in Q4 2023 and bottomed at $804.0 million in Q4 2021.
  • Average Total Current Liabilities over 4 years is $1.0 billion, with a median of $985.0 million recorded in 2025.
  • The widest YoY moves for Total Current Liabilities: up 27.87% in 2024, down 27.87% in 2024.
  • A 4-year view of Total Current Liabilities shows it stood at $804.0 million in 2021, then soared by 59.33% to $1.3 billion in 2023, then dropped by 27.87% to $924.0 million in 2024, then increased by 4.44% to $965.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $965.0 million in Q3 2025, $1.1 billion in Q2 2025, and $1.0 billion in Q1 2025.